Mohammad Rizwanullah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mohammad Rizwanullah has a total of 198 co-authors. Here are the top co-authors by number of shared publications:
- Javed Ahmad
Department of Pharmaceutics, College of Pharmacy, Najran University, Najran 11001, Saudi Arabia
14 shared publications - Syed Sarim Imam
Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
12 shared publications Saima Amin
Department of Pharmaceutics, School of Pharmaceutical Education & Research, Jamia Hamdard, New Delhi-110062,India
11 shared publications- Saima Amin
Department of Pharmaceutics, School of Pharmaceutical Education and Research, New Delhi, India
8 shared publications - Sultan Alshehri
Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
8 shared publications - Mohammad Zaki Ahmad
Department of Pharmaceutics, College of Pharmacy, Najran University
6 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-34
Intranasal Biodegradable Nanomedicine for Epilepsy Management: Targeting the Brain Beyond the Blood-Brain Barrier
Epilepsy is a common chronic neurological disorder characterized by recurrent, unprovoked seizures arising from abnormal neuronal hyperexcitability and hypersynchronous electrical activity within the brain. Despite advances in antiseizure medications, effective epilepsy management remains challenging because of pharmacoresistance, limited blood-brain barrier (BBB) permeability, inadequate intracerebral drug accumulation, and systemic toxicity. Moreover, currently available therapies primarily provide symptomatic seizure control without addressing the fundamental pathological processes involved in epileptogenesis, neuroinflammation, oxidative stress, and neuronal degeneration. Intranasal administration has emerged as an attractive non-invasive approach for direct brain targeting, enabling therapeutic agents to circumvent BBB-associated transport barriers and access the central nervous system through the olfactory and trigeminal neural pathways. In this context, biodegradable nanomedicine platforms have gained considerable attention due to their favorable biocompatibility, controlled drug release, enhanced mucosal permeation, and potential for targeted intracerebral delivery. This review provides a comprehensive and critical overview of recent advances in intranasal biodegradable nanomedicine for epilepsy, integrating current knowledge on disease pathophysiology, biological and pharmaceutical barriers, nose-to-brain transport mechanisms, biodegradable nanoparticle platforms, and emerging functionalization strategies. Importantly, the review critically evaluates the current evidence, distinguishing encouraging preclinical findings and discusses the major translational challenges that continue to hinder clinical implementation. Finally, future perspectives are highlighted to identify opportunities for developing safer, more effective, and clinically translatable therapies for epilepsy management.
- 1 July 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-34
Open AccessIntranasal Biodegradable Nanomedicine for Epilepsy Management: Targeting the Brain Beyond the Blood-Brain Barrier
Epilepsy is a common chronic neurological disorder characterized by recurrent, unprovoked seizures arising from abnormal neuronal hyperexcitability and hypersynchronous electrical activity within the brain. Despite advances in antiseizure medications, effective epilepsy management remains challenging because of pharmacoresistance, limited blood-brain barrier (BBB) permeability, inadequate intracerebral drug accumulation, and systemic toxicity. Moreover, currently available therapies primarily provide symptomatic seizure control without addressing the fundamental pathological processes involved in epileptogenesis, neuroinflammation, oxidative stress, and neuronal degeneration. Intranasal administration has emerged as an attractive non-invasive approach for direct brain targeting, enabling therapeutic agents to circumvent BBB-associated transport barriers and access the central nervous system through the olfactory and trigeminal neural pathways. In this context, biodegradable nanomedicine platforms have gained considerable attention due to their favorable biocompatibility, controlled drug release, enhanced mucosal permeation, and potential for targeted intracerebral delivery. This review provides a comprehensive and critical overview of recent advances in intranasal biodegradable nanomedicine for epilepsy, integrating current knowledge on disease pathophysiology, biological and pharmaceutical barriers, nose-to-brain transport mechanisms, biodegradable nanoparticle platforms, and emerging functionalization strategies. Importantly, the review critically evaluates the current evidence, distinguishing encouraging preclinical findings and discusses the major translational challenges that continue to hinder clinical implementation. Finally, future perspectives are highlighted to identify opportunities for developing safer, more effective, and clinically translatable therapies for epilepsy management.
- Open Access
- 19 May 2026
- Published by Elsevier in Nano Trends
- Vol. 14
Natural polysaccharide-derived nanocarriers for targeted paclitaxel delivery in cancer therapy: Recent progress and future directions
- 19 May 2026
- Published by Elsevier in Nano Trends
- Vol. 14
Open AccessNatural polysaccharide-derived nanocarriers for targeted paclitaxel delivery in cancer therapy: Recent progress and future directions
- Open Access
- 1 January 2026
- Published by XMLink in Clinical and Experimental Vaccine Research
- Vol. 15 (4) , 229
Biomimetic nanoparticles for cancer vaccines and immunotherapy: mechanisms, tumor microenvironment reprogramming, and translational perspectives
Shahab MS, et al. Clin Exp Vaccine Res. 2026 ;15:e23. https://doi.org/10.7774/cevr.2026.15.e23
- 1 January 2026
- Published by XMLink in Clinical and Experimental Vaccine Research
- Vol. 15 (4) , 229
Open AccessBiomimetic nanoparticles for cancer vaccines and immunotherapy: mechanisms, tumor microenvironment reprogramming, and translational perspectives
Shahab MS, et al. Clin Exp Vaccine Res. 2026 ;15:e23. https://doi.org/10.7774/cevr.2026.15.e23
- 26 November 2025
- Published by Elsevier in Pathology - Research and Practice
- Vol. 277, 156308
Progress in nanotechnology-based strategies to enhance tamoxifen therapy for breast cancer management
- 26 November 2025
- Published by Elsevier in Pathology - Research and Practice
- Vol. 277, 156308
Progress in nanotechnology-based strategies to enhance tamoxifen therapy for breast cancer management
- 6 November 2025
- Published by Wiley in WIREs Nanomedicine and Nanobiotechnology
- Vol. 17 (6) , e70040
Harnessing the Power of D‐Alpha‐Tocopheryl Polyethylene Glycol Succinate‐Based Nanoparticles for Targeted Breast Cancer Therapy
Breast cancer (BC) continues to be the most common cancer affecting women globally, posing significant therapeutic challenges due to limited therapeutic efficacy, non‐specific drug targeting, systemic toxicity, and the emergence of chemoresistance. These hurdles emphasize the critical need for novel and effective treatment strategies. Nanomedicine has revolutionized cancer therapy, especially D‐alpha‐tocopheryl polyethylene glycol succinate (TPGS)‐based nanoparticles (TPGS‐NPs), which have emerged as a promising strategy due to their enhanced therapeutic potential. TPGS, an amphiphilic derivative of Vitamin E, not only enhances the solubility, stability, and bioavailability of lipophilic drugs but also exhibits intrinsic anti‐BC properties. The incorporation of TPGS into NPs significantly enhances their physicochemical properties. Further, the engineering of TPGS‐NPs with targeting ligands significantly improves their specificity towards cancer cells. Also, TPGS‐NPs show great potential to improve photothermal and photodynamic therapies due to their excellent physicochemical properties. Moreover, TPGS‐NPs demonstrate an excellent ability for gene (plasmid DNA, siRNA, and miRNA) delivery by enhancing stability and transfection efficiency. This review explores the multifaceted role of TPGS and the role of different TPGS‐NPs in circumventing the limitations of conventional chemotherapy in BC treatment. Overall, developing TPGS‐NPs offers a versatile and multifaceted approach to achieve better therapeutic outcomes against BC. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease
- 6 November 2025
- Published by Wiley in WIREs Nanomedicine and Nanobiotechnology
- Vol. 17 (6) , e70040
Harnessing the Power of D‐Alpha‐Tocopheryl Polyethylene Glycol Succinate‐Based Nanoparticles for Targeted Breast Cancer Therapy
Breast cancer (BC) continues to be the most common cancer affecting women globally, posing significant therapeutic challenges due to limited therapeutic efficacy, non‐specific drug targeting, systemic toxicity, and the emergence of chemoresistance. These hurdles emphasize the critical need for novel and effective treatment strategies. Nanomedicine has revolutionized cancer therapy, especially D‐alpha‐tocopheryl polyethylene glycol succinate (TPGS)‐based nanoparticles (TPGS‐NPs), which have emerged as a promising strategy due to their enhanced therapeutic potential. TPGS, an amphiphilic derivative of Vitamin E, not only enhances the solubility, stability, and bioavailability of lipophilic drugs but also exhibits intrinsic anti‐BC properties. The incorporation of TPGS into NPs significantly enhances their physicochemical properties. Further, the engineering of TPGS‐NPs with targeting ligands significantly improves their specificity towards cancer cells. Also, TPGS‐NPs show great potential to improve photothermal and photodynamic therapies due to their excellent physicochemical properties. Moreover, TPGS‐NPs demonstrate an excellent ability for gene (plasmid DNA, siRNA, and miRNA) delivery by enhancing stability and transfection efficiency. This review explores the multifaceted role of TPGS and the role of different TPGS‐NPs in circumventing the limitations of conventional chemotherapy in BC treatment. Overall, developing TPGS‐NPs offers a versatile and multifaceted approach to achieve better therapeutic outcomes against BC. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease
- Open Access
- 14 October 2025
- Published by Maad Rayan Publishing Company in BioImpacts
- Vol. 15 (1) , 31117
Recent advancement in polymeric nanoparticles for oral chemotherapy: Transforming cancer treatment
Oral chemotherapy offers an attractive alternative to conventional intravenous administration by providing high patient compliance and improved treatment adherence. However, several challenges, like poor drug solubility, enzymatic degradation, and extensive first-pass metabolism, have significantly limited the oral bioavailability of chemotherapeutic agents. Recently, polymeric nanoparticles (PNPs) have become an alternative strategy to overcome these challenges and revolutionize the oral chemotherapeutic approach. PNPs offer unique advantages, including drug protection from harsh gastrointestinal conditions, controlled release profiles, and enhanced mucosal adhesion, which collectively improve drug absorption and therapeutic efficacy. Additionally, surface-modified PNPs can bypass efflux transporters such as P-glycoprotein and promote receptor-mediated endocytosis to achieve targeted delivery and minimize systemic toxicity. While these advancements highlight the transformative potential of PNPs in oral chemotherapy, potential clinical challenges such as scalability, reproducibility, and regulatory hurdles must be addressed to enable successful clinical translation. The present review comprehensively explores the role of PNPs in enhancing the oral delivery of cancer therapeutics, emphasizing strategies to improve drug stability, prolong gastrointestinal retention, and facilitate efficient cellular uptake. The advancements discussed herein underscore the transformative potential of PNPs as a pivotal approach for improving oral chemotherapy outcomes and expanding therapeutic possibilities in cancer management.
- 14 October 2025
- Published by Maad Rayan Publishing Company in BioImpacts
- Vol. 15 (1) , 31117
Open AccessRecent advancement in polymeric nanoparticles for oral chemotherapy: Transforming cancer treatment
Oral chemotherapy offers an attractive alternative to conventional intravenous administration by providing high patient compliance and improved treatment adherence. However, several challenges, like poor drug solubility, enzymatic degradation, and extensive first-pass metabolism, have significantly limited the oral bioavailability of chemotherapeutic agents. Recently, polymeric nanoparticles (PNPs) have become an alternative strategy to overcome these challenges and revolutionize the oral chemotherapeutic approach. PNPs offer unique advantages, including drug protection from harsh gastrointestinal conditions, controlled release profiles, and enhanced mucosal adhesion, which collectively improve drug absorption and therapeutic efficacy. Additionally, surface-modified PNPs can bypass efflux transporters such as P-glycoprotein and promote receptor-mediated endocytosis to achieve targeted delivery and minimize systemic toxicity. While these advancements highlight the transformative potential of PNPs in oral chemotherapy, potential clinical challenges such as scalability, reproducibility, and regulatory hurdles must be addressed to enable successful clinical translation. The present review comprehensively explores the role of PNPs in enhancing the oral delivery of cancer therapeutics, emphasizing strategies to improve drug stability, prolong gastrointestinal retention, and facilitate efficient cellular uptake. The advancements discussed herein underscore the transformative potential of PNPs as a pivotal approach for improving oral chemotherapy outcomes and expanding therapeutic possibilities in cancer management.
- Open Access
- 26 July 2025
- Published by Maad Rayan Publishing Company in BioImpacts
- Vol. 15 (1) , 30860
Lipid-based nanoparticles: advancing therapeutic strategies for vitiligo management
Vitiligo, a chronic autoimmune disorder characterized by the presence of depigmented skin patches, remains a therapeutic challenge due to its multifactorial pathogenesis and the absence of highly effective treatment options. Although the exact etiology of vitiligo is not fully understood, factors such as genetic factors, oxidative stress, autoimmunity, and inflammation are implicated in the destruction of melanocytes. Current therapeutic strategies primarily focus on modulating immune responses and alleviating oxidative stress. Conventional treatments, including topical corticosteroids, phototherapy, and immunosuppressive agents, often exhibit limited efficacy and are associated with significant side effects, limiting their long-term application. In recent years, nanotechnology has emerged as a transformative approach in drug delivery systems, offering precise targeting, enhanced drug bioavailability, and minimized systemic toxicity. Nanocarrier-based systems especially lipid-based nanoparticles (LNPs) effectively address critical barriers in vitiligo treatment, such as poor drug solubility, rapid degradation, and inadequate skin penetration. Moreover, controlled drug release mechanisms offered by LNPs ensure sustained therapeutic drug levels at the target site, improving efficacy and reducing the frequency of administration. This review provides an overview of vitiligo, its pathogenesis, and the limitations of conventional treatments while highlighting recent advancements in LNPs-based drug delivery systems as a promising strategy for the effective management of vitiligo.
- 26 July 2025
- Published by Maad Rayan Publishing Company in BioImpacts
- Vol. 15 (1) , 30860
Open AccessLipid-based nanoparticles: advancing therapeutic strategies for vitiligo management
Vitiligo, a chronic autoimmune disorder characterized by the presence of depigmented skin patches, remains a therapeutic challenge due to its multifactorial pathogenesis and the absence of highly effective treatment options. Although the exact etiology of vitiligo is not fully understood, factors such as genetic factors, oxidative stress, autoimmunity, and inflammation are implicated in the destruction of melanocytes. Current therapeutic strategies primarily focus on modulating immune responses and alleviating oxidative stress. Conventional treatments, including topical corticosteroids, phototherapy, and immunosuppressive agents, often exhibit limited efficacy and are associated with significant side effects, limiting their long-term application. In recent years, nanotechnology has emerged as a transformative approach in drug delivery systems, offering precise targeting, enhanced drug bioavailability, and minimized systemic toxicity. Nanocarrier-based systems especially lipid-based nanoparticles (LNPs) effectively address critical barriers in vitiligo treatment, such as poor drug solubility, rapid degradation, and inadequate skin penetration. Moreover, controlled drug release mechanisms offered by LNPs ensure sustained therapeutic drug levels at the target site, improving efficacy and reducing the frequency of administration. This review provides an overview of vitiligo, its pathogenesis, and the limitations of conventional treatments while highlighting recent advancements in LNPs-based drug delivery systems as a promising strategy for the effective management of vitiligo.
- 9 May 2025
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 678, 125687
Exploring the therapeutic potential of ligand-decorated nanostructured lipid carriers for targeted solid tumor therapy
- 9 May 2025
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 678, 125687
Exploring the therapeutic potential of ligand-decorated nanostructured lipid carriers for targeted solid tumor therapy
- Open Access
- 22 November 2024
- Published by Beilstein Institut in Beilstein Journal of Nanotechnology
- Vol. 15 (1) , 1473-1497
Polymer lipid hybrid nanoparticles for phytochemical delivery: challenges, progress, and future prospects
Phytochemicals, naturally occurring compounds in plants, possess a wide range of therapeutic properties, including antioxidant, anti-inflammatory, anticancer, and antimicrobial activities. However, their clinical application is often hindered by poor water solubility, low bioavailability, rapid metabolism, and instability under physiological conditions. Polymer lipid hybrid nanoparticles (PLHNPs) have emerged as a novel delivery system that combines the advantages of both polymeric and lipid-based nanoparticles to overcome these challenges. This review explores the potential of PLHNPs to enhance the delivery and efficacy of phytochemicals for biomedical applications. We discuss the obstacles in the conventional delivery of phytochemicals, the fundamental architecture of PLHNPs, and the types of PLHNPs, highlighting their ability to improve encapsulation efficiency, stability, and controlled release of the encapsulated phytochemicals. In addition, the surface modification strategies to improve overall therapeutic efficacy by site-specific delivery of encapsulated phytochemicals are also discussed. Furthermore, we extensively discuss the preclinical studies on phytochemical encapsulated PLHNPs for the management of different diseases. Additionally, we explore the challenges ahead and prospects of PLHNPs regarding their widespread use in clinical settings. Overall, PLHNPs hold strong potential for the effective delivery of phytochemicals for biomedical applications. As per the findings from pre-clinical studies, this may offer a promising strategy for managing various diseases.
- 22 November 2024
- Published by Beilstein Institut in Beilstein Journal of Nanotechnology
- Vol. 15 (1) , 1473-1497
Open AccessPolymer lipid hybrid nanoparticles for phytochemical delivery: challenges, progress, and future prospects
Phytochemicals, naturally occurring compounds in plants, possess a wide range of therapeutic properties, including antioxidant, anti-inflammatory, anticancer, and antimicrobial activities. However, their clinical application is often hindered by poor water solubility, low bioavailability, rapid metabolism, and instability under physiological conditions. Polymer lipid hybrid nanoparticles (PLHNPs) have emerged as a novel delivery system that combines the advantages of both polymeric and lipid-based nanoparticles to overcome these challenges. This review explores the potential of PLHNPs to enhance the delivery and efficacy of phytochemicals for biomedical applications. We discuss the obstacles in the conventional delivery of phytochemicals, the fundamental architecture of PLHNPs, and the types of PLHNPs, highlighting their ability to improve encapsulation efficiency, stability, and controlled release of the encapsulated phytochemicals. In addition, the surface modification strategies to improve overall therapeutic efficacy by site-specific delivery of encapsulated phytochemicals are also discussed. Furthermore, we extensively discuss the preclinical studies on phytochemical encapsulated PLHNPs for the management of different diseases. Additionally, we explore the challenges ahead and prospects of PLHNPs regarding their widespread use in clinical settings. Overall, PLHNPs hold strong potential for the effective delivery of phytochemicals for biomedical applications. As per the findings from pre-clinical studies, this may offer a promising strategy for managing various diseases.